Compare Crispr Therapeutics AG (CRSP) vs Fubotv Inc (FUBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fubotv Inc — how do they compare? Crispr Therapeutics AG trades at $48.65 (market cap $5.06B), while Fubotv Inc trades at $10.2 (market cap $302.39M). The key difference: Crispr Therapeutics AG is far larger — about 16.7× Fubotv Inc's market cap. Which is the better fit depends on your goals.
| CRSP | FUBO | |
|---|---|---|
Market Cap | $5.06B | $302.39M |
Sector | Health | Technology |
52-Week High | $76.78 | $54.72 |
52-Week Low | $44.34 | $8.09 |
Enterprise Value | $3.40B | $472.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $48.60, down 3.69% on the day, reflecting ongoing volatility. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal deep losses: gross margin -20.09%, net margin -56,853.4% in 2025. Recent Q1 2026 EPS missed expectations at -$1.28. However, analyst consensus remains bullish with a $74.50 price target, supported by Casgevy's FDA approval and pediatric expansion.
Outlook balances high growth potential in gene editing against significant financial risks. The company's robust cash position ($49.30M net inflow in 2025) and strong buy ratings (57.9% of analysts) suggest long-term opportunity, but persistent losses and competitive pressures require caution. Investors face upside from clinical successes versus downside from execution challenges and burn rate concerns.
FUBO stock trades at $10.46, up 9.64% on the day, with a bullish technical signal and strong analyst support. The company shows improving fundamentals, with revenue reaching $1.62B in 2024 and a projected net profit of $123M in 2025. Recent CEO appointment of former Disney+ executive Alisa Bowen has driven positive sentiment, while valuation ratios like P/E of 2.67 and P/S of 0.21 appear attractive relative to historical norms.
The outlook for FUBO is cautiously optimistic, with upside to the $16.25 consensus price target, but risks include persistent cash flow challenges and intense streaming competition. Investors should weigh the potential for profitability growth against execution risks in a crowded market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
